CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Chloroquine or hydroxychloroquineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2916 Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki 1.00
drug2914 Thrombin Generation Assay (TGA) Wiki 1.00

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D004211 Disseminated Intravascular Coagulation NIH 0.50
D020141 Hemostatic Disorders NIH 0.27
D001778 Blood Coagulation Disorders NIH 0.27
D016638 Critical Illness NIH 0.13
D014777 Virus Diseases NIH 0.12
D007239 Infection NIH 0.05

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0005521 Disseminated intravascular coagulation HPO 0.50
HP:0001928 Abnormality of coagulation HPO 0.27

There is one clinical trial.

Clinical Trials

1 Multi-centre Randomised Controlled Trial of Chloroquine/Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa

Clinical manifestations of Covid-19 are poorly characterised in HIV co-infection, which may predispose to more severe disease. Reducing hospitalisation and severe illness in this population has important individual and public health benefits. The investigators propose a pragmatic multi-centre, randomized controlled trial in South Africa to evaluate the efficacy and safety of chloroquine or hydroxychloroquine to prevent progression of disease and hospitalisation amongst HIV-positive people with Covid-19 not requiring hospitalisation at initial assessment.

NCT04360759 Covid-19 HIV Drug: Chloroquine or hydroxychloroquine

Primary Outcomes

Description: Events defined as Hospitalisation or Death

Measure: Event-free survival at 28 days post-randomization between experimental group and standard of care group

Time: Day 28

Secondary Outcomes

Measure: Incidence of serious adverse events

Time: Day 28

Measure: Incidence of adverse events of special interest related to investigational product at time of hospitalisation

Time: Day 28

Measure: Premature discontinuation of treatment

Time: Day 28

Measure: Time from treatment initiation to death, ARDS (PF/SF ratio < 300), or mechanical ventilation

Time: Day 28

Measure: Proportion with moderate and severe ARDS

Time: Day 28

Measure: Duration of hospitalisation and ICU stay in survivors

Time: Day 28

Measure: Incidence of Covid-19 in household contacts

Time: Day 28

No related HPO nodes (Using clinical trials)